In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coley Pharmaceutical

Latest From Coley Pharmaceutical

Appointments: Gilead, Biogen, Nordic Nanovector, Neon Therapeutics, Achaogen and vasopharm

This week's roundup includes executive appointments by Gilead Sciences, Nordic Nanovector, Mereo BioPharma, vasopharm and Rigontec. Biogen has also appointed two executives to its planned spin-off company, Bioverativ.

Executive Changes

Pfizer Oncology: Big Strides But Not Blockbuster Size

Pfizer’s emphasis on oncology has yielded three new drug approvals in the last 20 months and another two promising drugs on the horizon. It is a notable achievement, but investors may be wondering when the results are going to be felt on the top line.

BioPharmaceutical Clinical Trials

Verastem Joins The Public Markets With A Strong IPO

Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.

BioPharmaceutical Business Strategies

Financings Of The Fortnight Applies Its Own Lens To Early-Stage Investments

Plus news on recent financings by Neurocrine Biosciences, Prosensa, RaNA Therapeutics and Trius Therapeutics.

BioPharmaceutical Business Strategies
See All

Company Information

UsernamePublicRestriction

Register